| 2001 | Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
| CANCER RESEARCH AND TREATMENT |
| 2022 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
| ONCOTARGET |
| 2019 | Establishment of Chemosensitivity Tests in Triple-Negative and BRCA-mutated Breast Cancer Patient-Derived Xenograft Models
| PLOS ONE |
| 2018 | External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence
| Radiation Oncology Journal |
| 2017 | Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
| CANCER RESEARCH AND TREATMENT |
| 2018 | Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
| CANCER RESEARCH AND TREATMENT |
| 2021 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer
| INTERNATIONAL JOURNAL OF CANCER |
| 2005 | Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2021 | Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
| JCO PRECISION ONCOLOGY |
| 2020 | Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
| ONCOLOGIST |
| 2023 | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK |
| 2023 | Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
| CANCER RESEARCH AND TREATMENT |
| 2016 | Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
| JOURNAL OF BREAST CANCER |
| 2003 | Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein
| CANCER RESEARCH AND TREATMENT |
| 2021 | Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy
| SCIENTIFIC REPORTS |
| 2003 | Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2003 | Infusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2023 | Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA
| NATURE COMMUNICATIONS |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2012 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. | LANCET |
| 2021 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study | EUROPEAN JOURNAL OF CANCER |
| 2020 | Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis | BREAST CARE |
| 2018 | Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective | CLINICAL BREAST CANCER |
| 2022 | Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
| ANNALS OF ONCOLOGY |
| 2023 | Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
| DIAGNOSTICS |
| 2016 | Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
| PLOS ONE |
| 2021 | Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
| ONCOLOGIST |
| 2006 | Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin | HUMAN GENE THERAPY |
| 2017 | Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
| JOURNAL OF BREAST CANCER |
| 2012 | Metaplastic breast cancer: clinicopathological features and its prognosis | JOURNAL OF CLINICAL PATHOLOGY |
| 2022 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
| CANCERS |
| 2011 | Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer | ONCOLOGY |
| 2021 | Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
| PHARMACEUTICALS |
| 2017 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
| 2017 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2007 | Multi-disciplinary treatment of a rare pelvic cavity ependymoma
| YONSEI MEDICAL JOURNAL |
| 2013 | Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
| ANNALS OF ONCOLOGY |
| 2020 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial | LANCET |
| 2017 | Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
| ANNALS OF SURGICAL TREATMENT AND RESEARCH |
| 2020 | Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
| SCIENTIFIC REPORTS |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 2003 | Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2006 | Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer | ONCOLOGY REPORTS |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2023 | Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2014 | Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer | CANCER |
| 2020 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study | ANNALS OF ONCOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2007 | Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib | JOURNAL OF CLINICAL ONCOLOGY |
| 2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2009 | Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma | ONCOLOGY |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 2007 | Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
| CANCER |
